|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2016. CA Cancer J Clin. 66:7–30. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Editorial board of the cancer statistics
in japan. Cancer statistic in Japan 2017. Tokyo: Foundation for
promotion of cancer research; 2017. https://ganjoho.jp/data/reg_stat/statistics/bro-chure/2017/cancer_statistics_2017.pdf16–July.
2018
|
|
3
|
Babjuk M, Burger M, Zigeuner R, Shariat
SF, van Rhijn BW, Compérat E, Sylvester RJ, Kaasinen E, Böhle A,
Palou Redorta J, et al: EAU guidelines on non-muscle-invasive
urothelial carcinoma of the bladder: Update 2013. Eur Urol.
64:639–653. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Miyake M, Fujimoto K and Hirao Y: Active
surveillance for nonmuscle invasive bladder cancer. Investig Clin
Urol. 57 Suppl 1:S4–S13. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Herr HW: Intravesical bacillus
Calmette-Guerin outcomes in patients with bladder cancer and
asymptomatic bacteriuria. J Urol. 187:435–437. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Shahin O, Thalmann GN, Rentsch C,
Mazzucchelli L and Studer UE: A retrospective analysis of 153
patients treated with or without intravesical bacillus
Calmette-Guerin for primary stage T1 grade 3 bladder cancer:
Recurrence, progression and survival. J Urol. 169:96–100. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Herr HW and Morales A: History of Bacillus
Calmette-Guerin and bladder cancer: An immunotherapy success story.
J Urol. 179:53–56. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Lamm DL, Blumenstein BA, Crissman JD,
Montie JE, Gottesman JE, Lowe BA, Sarosdy MF, Bohl RD, Grossman HB,
Beck TM, et al: Maintenance bacillus Calmette-Guérin immunotherapy
for recurrent TA, T1 and carcinoma in situ transitional cell
carcinoma of the bladder: A randomized Southwest Oncology Group
Study. J Urol. 163:1124–1129. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Nakai Y, Anai S, Tanaka N, Chihara Y,
Haramoto M, Otani T, Nakagawa Y, Hirao Y, Konishi N and Fujimoto K:
Insignificant role of bacillus Calmette-Guérin maintenance therapy
after complete transurethral resection of bladder tumor for
intermediate- and high-risk non-muscle-invasive bladder cancer:
Results from a randomized trial. Int J Urol. 23:854–860. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Oosterlinck W, Kirkali Z, Sylvester R, da
Silva FC, Busch C, Algaba F, Collette S and Bono A: Sequential
intravesical chemoimmunotherapy with mitomycin C and bacillus
Calmette-Guérin and with bacillus Calmette-Guérin alone in patients
with carcinoma in situ of the urinary bladder: Results of an EORTC
genito-urinary group randomized phase 2 trial (30993). Eur Urol.
59:438–446. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Solsona E, Madero R, Chantada V, Fernandez
JM, Zabala JA, Portillo JA, Alonso JM, Astobieta A, Unda M,
Martinez-Piñeiro L, et al: Sequential combination of mitomycin C
plus bacillus Calmette-Guérin (BCG) is more effective but more
toxic than BCG alone in patients with non-muscle-invasive bladder
cancer in intermediate- and high-risk patients: Final outcome of
CUETO 93009, a randomized prospective trial. Eur Urol. 67:508–516.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Witjes JA, Caris CT, Mungan NA, Debruyne
FM and Witjes WP: Results of a randomized phase III trial of
sequential intravesical therapy with mitomycin C and bacillus
Calmette-Guerin versus mitomycin C alone in patients with
superficial bladder cancer. J Urol. 160:1668–1671. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Kaasinen E, Rintala E, Pere AK, Kallio J,
Puolakka VM, Liukkonen T and Tuhkanen K: Weekly mitomycin C
followed by monthly bacillus Calmette-Guerin or alternating monthly
interferon-alpha2B and bacillus Calmette-Guerin for prophylaxis of
recurrent papillary superficial bladder carcinoma. J Urol.
164:47–52. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Rintala E, Jauhiainen K, Kaasinen E, Nurmi
M and Alfthan O: Alternating mitomycin C and bacillus
Calmette-Guerin instillation prophylaxis for recurrent papillary
(stages Ta to T1) superficial bladder cancer. Finnbladder Group. J
Urol. 156:56–60. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Di Stasi SM, Giannantoni A, Giurioli A,
Valenti M, Zampa G, Storti L, Attisani F, De Carolis A, Capelli G,
Vespasiani G, et al: Sequential BCG and electromotive mitomycin
versus BCG alone for high-risk superficial bladder cancer: A
randomised controlled trial. Lancet Oncol. 7:43–51. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Kaasinen E, Wijkström H, Malmström PU,
Hellsten S, Duchek M, Mestad O and Rintala E; Nordic Urothelial
Cancer Group, : Alternating mitomycin C and BCG instillations
versus BCG alone in treatment of carcinoma in situ of the urinary
bladder: A nordic study. Eur Urol. 43:637–645. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Bilen CY, Ozen H, Aki FT, Aygün C, Ekici S
and Kendi S: Clinical experience with BCG alone versus BCG plus
epirubicin. Int J Urol. 7:206–209. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Hilton WM, Ercole B, Parekh DJ, Sonpavde
G, Ghosh R and Svatek RS: Efficacy of combined intravesical
immunotherapy and chemotherapy for non-muscle invasive bladder
cancer. Expert Rev Anticancer Ther. 11:949–957. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Rintala E, Jauhiainen K, Rajala P, Ruutu
M, Kaasinen E and Alfthan O: Alternating mitomycin C and bacillus
Calmette-Guerin instillation therapy for carcinoma in situ of the
bladder. The Finnbladder Group. J Urol. 154:2050–2053. 1995.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Kaasinen E, Rintala E, Hellström P,
Viitanen J, Juusela H, Rajala P, Korhonen H and Liukkonen T;
FinnBladder Group, : Factors explaining recurrence in patients
undergoing chemoimmunotherapy regimens for frequently recurring
superficial bladder carcinoma l. Eur Urol. 42:167–174. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Van der Meijden AP, Hall RR, Macaluso MP,
Pawinsky A, Sylvester R and Van Glabbeke M: Marker tumour responses
to the sequential combination of intravesical therapy with
mitomycin-C and BCG-RIVM in multiple superficial bladder tumours.
Report from the European Organisation for Research and Treatment on
Cancer-Genitourinary Group (EORTC 30897). Eur Urol. 29:199–203.
1996.PubMed/NCBI
|
|
22
|
Miyake M, Tatsumi Y, Gotoh D, Ohnishi S,
Owari T, Iida K, Ohnishi K, Hori S, Morizawa Y, Itami Y, et al:
Regulatory T cells and tumor-associated macrophages in the tumor
microenvironment in non-muscle invasive bladder cancer treated with
intravesical bacille Calmette-Guérin: A long-term follow-up study
of a Japanese cohort. Int J Mol Sci. 18:E21862017. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Hori S, Miyake M, Tatsumi Y, Onishi S,
Morizawa Y, Nakai Y, Tanaka N and Fujimoto K: Topical and systemic
immunoreaction triggered by intravesical chemotherapy in an
N-butyl-N-(4-hydroxybutyl) nitorosamine induced bladder cancer
mouse model. PLoS One. 12:e01754942017. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Hori S, Miyake M, Tatsumi Y, Morizawa Y,
Nakai Y, Onishi S, Onishi K, Iida K, Gotoh D, Tanaka N and Fujimoto
K: Gamma-Klotho exhibits multiple roles in tumor growth of human
bladder cancer. Oncotarget. 9:19508–19524. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Hori S, Miyake M, Onishi S, Tatsumi Y,
Morizawa Y, Nakai Y, Anai S, Tanaka N and Fujimoto K: Clinical
significance of α- and β-Klotho in urothelial carcinoma of the
bladder. Oncol Rep. 36:2117–2125. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Kitamura H and Tsukamoto T: Immunotherapy
for urothelial carcinoma: Current status and perspectives. Cancers.
3:3055–3072. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Uekado Y, Hirano A, Shinka T and Ohkawa T:
The effects of intravesical chemoimmunotherapy with epirubicin and
bacillus Calmette-Guérin for prophylaxis of recurrence of
superficial bladder cancer: A preliminary report. Cancer Chemother
Pharmacol. 35 Suppl:S65–S68. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Erol A, Ozgür S, Basar M and Cetin S:
Trial with bacillus Calmette-Guérin and epirubicin combination in
the prophylaxis of superficial bladder cancer. Urol Int. 52:69–72.
1994. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Ali-El-Dein B, Nabeeh A, Ismail EH and
Ghoneim MA: Sequential bacillus Calmette-Guerin and epirubicin
versus bacillus Calmette-Guerin alone for superficial bladder
tumors: A randomized prospective study. J Urol. 162:339–342. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Bono AV, Lovisolo JA and Saredi G:
Transurethral resection and sequential chemo-immunoprophylaxis in
primary T1G3 bladder cancer. Eur Urol. 37:478–483. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Cai T, Nesi G, Tinacci G, Zini E, Mondaini
N, Boddi V, Mazzoli S and Bartoletti R: Can early single dose
instillation of epirubicin improve bacillus Calmette-Guerin
efficacy in patients with nonmuscle invasive high risk bladder
cancer? Results from a prospective, randomized, double-blind
controlled study. J Urol. 180:110–115. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Järvinen R, Kaasinen E, Rintala E and
Group TF: Long-term results of maintenance treatment of mitomycin C
or alternating mitomycin C and bacillus Calmette-Guérin
instillation therapy of patients with carcinoma in situ of the
bladder: A subgroup analysis of the prospective FinnBladder 2 study
with a 17-year follow-up. Scand J Urol Nephrol. 46:411–417. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Ghiringhelli F, Larmonier N, Schmitt E,
Parcellier A, Cathelin D, Garrido C, Chauffert B, Solary E,
Bonnotte B and Martin F: CD4+CD25+ regulatory
T cells suppress tumor immunity but are sensitive to
cyclophosphamide which allows immunotherapy of established tumors
to be curative. Eur J Immunol. 34:336–344. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Sakaguchi S, Sakaguchi N, Shimizu J,
Yamazaki S, Sakihama T, Itoh M, Kuniyasu Y, Nomura T, Toda M and
Takahashi T: Immunologic tolerance maintained by CD25+
CD4+ regulatory T cells: Their common role in
controlling autoimmunity, tumor immunity, and transplantation
tolerance. Immunol Rev. 182:18–32. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Gabrilovich DI and Nagarai S:
Myeloid-derived suppressor cells as regulators of the immune
system. Nat Rev Immunol. 9:162–174. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Zhao Y, Wang D, Xu T, Liu P, Cao Y, Wang
Y, Yang X, Xu X, Wang X and Niu H: Bladder cancer cells re-educate
TAMs through lactate shuttling in the microfluidic cancer
microenvironment. Oncotarget. 6:39196–39210. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Svatek RS, Zhao XR, Morales EE, Jha MK,
Tseng TY, Hugen CM, Hurez V, Hernandez J and Curiel TJ: Sequential
intravesical mitomycin plus Bacillus Calmette-Guérin for
non-muscle-invasive urothelial bladder carcinoma: Translational and
phase I clinical trial. Clin Cancer Res. 21:303–311. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Obeid M, Tesniere A, Ghiringhelli F, Fimia
GM, Apetoh L, Perfettini JL, Castedo M, Mignot G, Panaretakis T,
Casares N, et al: Calreticulin exposure dictates the immunogenicity
of cancer cell death. Nat Med. 13:54–61. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Ramakrishnan R, Assudani D, Nagaraj S,
Hunter T, Cho HI, Antonia S, Altiok S, Celis E and Gabrilovich DI:
Chemotherapy enhances tumor cell susceptibility to CTL-medeated
killing during cancer immunotherapy in mice. J Clin Invest.
120:1111–1124. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Alizadeh D, Trad M, Hanke NT, Larmonier
CB, Janikashvili N, Bonnotte B, Katsanis E and Larmonier N:
Doxorubicin eliminates myeloid-derived suppressor cells and
enhances the efficacy of adoptive T-cell transfer in breast cancer.
Cancer Res. 74:104–118. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Saban MR, Simpson C, Davis C, Wallis G,
Knowlton N, Frank MB, Centola M, Gallucci RM and Saban R:
Discriminators of mouse bladder response to intravesical Bacillus
Calmette-Guerin (BCG). BMC Immunol. 8:62007. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Shintani Y, Sawada Y, Inagaki T, Kohjimoto
Y, Ueoka Y and Shinka T: Intravesical instillation therapy with
bacillus Calmette-Guérin for superficial bladder cancer: Study of
the mechanism of bacillus Calmette-Guérin immunotherapy. Int J
Urol. 14:140–146. 2007. View Article : Google Scholar : PubMed/NCBI
|
